Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Using CRISPR gene editing technology, researchers from Jiangnan University in China took a fungus that is already used as a ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

India has launched BIRSA 101, the nation’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a ...

Launching the therapy, Dr. Jitendra Singh declared that India has officially begun its decisive march toward a Sickle ...

In a major leap for Atmanirbhar Bharat and India’s genomic medicine capabilities, the government on Wednesday launched the ...

ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent ...

A single multipurpose gene-editing tool can correct several genetic conditions by restoring proteins that have been truncated ...

CRISPR has turned a simple fungus into a fast-growing, meat-like protein source with impressively low environmental impact.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...